These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32502343)

  • 1. Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13.
    Liu Y; Hao M; Leggett AL; Gao Y; Ficarro SB; Che J; He Z; Olson CM; Marto JA; Kwiatkowski NP; Zhang T; Gray NS
    J Med Chem; 2020 Jul; 63(13):6708-6726. PubMed ID: 32502343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
    Zhang T; Kwiatkowski N; Olson CM; Dixon-Clarke SE; Abraham BJ; Greifenberg AK; Ficarro SB; Elkins JM; Liang Y; Hannett NM; Manz T; Hao M; Bartkowiak B; Greenleaf AL; Marto JA; Geyer M; Bullock AN; Young RA; Gray NS
    Nat Chem Biol; 2016 Oct; 12(10):876-84. PubMed ID: 27571479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma.
    Jiang B; Jiang J; Kaltheuner IH; Iniguez AB; Anand K; Ferguson FM; Ficarro SB; Seong BKA; Greifenberg AK; Dust S; Kwiatkowski NP; Marto JA; Stegmaier K; Zhang T; Geyer M; Gray NS
    Eur J Med Chem; 2021 Oct; 221():113481. PubMed ID: 33945934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
    Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
    Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
    Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
    Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
    Ito M; Tanaka T; Toita A; Uchiyama N; Kokubo H; Morishita N; Klein MG; Zou H; Murakami M; Kondo M; Sameshima T; Araki S; Endo S; Kawamoto T; Morin GB; Aparicio SA; Nakanishi A; Maezaki H; Imaeda Y
    J Med Chem; 2018 Sep; 61(17):7710-7728. PubMed ID: 30067358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II.
    Cheng SW; Kuzyk MA; Moradian A; Ichu TA; Chang VC; Tien JF; Vollett SE; Griffith M; Marra MA; Morin GB
    Mol Cell Biol; 2012 Nov; 32(22):4691-704. PubMed ID: 22988298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
    Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
    Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
    Yang J; Chang Y; Tien JC; Wang Z; Zhou Y; Zhang P; Huang W; Vo J; Apel IJ; Wang C; Zeng VZ; Cheng Y; Li S; Wang GX; Chinnaiyan AM; Ding K
    J Med Chem; 2022 Aug; 65(16):11066-11083. PubMed ID: 35938508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and resistance mechanism of a selective CDK12 degrader.
    Jiang B; Gao Y; Che J; Lu W; Kaltheuner IH; Dries R; Kalocsay M; Berberich MJ; Jiang J; You I; Kwiatkowski N; Riching KM; Daniels DL; Sorger PK; Geyer M; Zhang T; Gray NS
    Nat Chem Biol; 2021 Jun; 17(6):675-683. PubMed ID: 33753926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
    Quereda V; Bayle S; Vena F; Frydman SM; Monastyrskyi A; Roush WR; Duckett DR
    Cancer Cell; 2019 Nov; 36(5):545-558.e7. PubMed ID: 31668947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK12 Activity-Dependent Phosphorylation Events in Human Cells.
    Bartkowiak B; Yan CM; Soderblom EJ; Greenleaf AL
    Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31652541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression, purification, and identification of associated proteins of the full-length hCDK12/CyclinK complex.
    Bartkowiak B; Greenleaf AL
    J Biol Chem; 2015 Jan; 290(3):1786-95. PubMed ID: 25429106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.
    Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
    Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promise and current status of CDK12/13 inhibition for the treatment of cancer.
    Tadesse S; Duckett DR; Monastyrskyi A
    Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation.
    Choi SH; Kim S; Jones KA
    Exp Mol Med; 2020 May; 52(5):762-771. PubMed ID: 32451425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype.
    Olson CM; Liang Y; Leggett A; Park WD; Li L; Mills CE; Elsarrag SZ; Ficarro SB; Zhang T; Düster R; Geyer M; Sim T; Marto JA; Sorger PK; Westover KD; Lin CY; Kwiatkowski N; Gray NS
    Cell Chem Biol; 2019 Jun; 26(6):792-803.e10. PubMed ID: 30905681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The structure and substrate specificity of human Cdk12/Cyclin K.
    Bösken CA; Farnung L; Hintermair C; Merzel Schachter M; Vogel-Bachmayr K; Blazek D; Anand K; Fisher RP; Eick D; Geyer M
    Nat Commun; 2014 Mar; 5():3505. PubMed ID: 24662513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
    Blazek D; Kohoutek J; Bartholomeeusen K; Johansen E; Hulinkova P; Luo Z; Cimermancic P; Ule J; Peterlin BM
    Genes Dev; 2011 Oct; 25(20):2158-72. PubMed ID: 22012619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.